Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia

Table 1

Comparison of patient parameters in older (≥80 years old) and younger (<60 years old) BTX-A therapeutic groups.

Clinical index	Older group	Younger group	value
Average age (years)	82.6 ± 2.9	49.5 ± 6.3	0.000
Gender (male/female)	4/10	10/19	0.968
Coexistent diseases (with/without)	6/8	1/28	0.005
Therapeutic doses (U)	91.3 ± 25.6	71.8 ± 33.1	0.061
D value of VAS (media, before and after treatment)	2.5	0	0.283
Side effect (total count)	2^a	2^b	0.825

^aWhole-body discomfort in one; mild left eye ptosis and slight oral deviation/drooling in the other; ^bMild facial paralysis in one; moderate facial paralysis in the other; BTX-A: botulinum toxin type A; VAS: visual analogue scale.